An expert presents the results of a phase 2 study on the impact of rituximab on myasthenia gravis.
Live from the American Academy of Neurology Annual Meeting, Neurology Times’ Dr. Andrew Wilner discusses the results of a phase 2 study on the impact of rituximab on myasthenia gravis (MG) with researcher Dr. Richard Nowak, Director of the Yale Myasthenia Clinic.
In the early course of the illness, MG can weaken a patient's arms, legs, sight/eyes, and facial musclature and compromise a one's ability to swallow, chew, talk, and even breathe. There is no known cure but immunosuppressive treatment can control symptoms. Although the results were not as anticipated, the study shares some insights into the care of patients with MG.
RELATED CONTENT: Finding Consensus: Treating Myasthenia Gravis